发明名称 |
METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS |
摘要 |
A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER 1 /Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly. |
申请公布号 |
WO2016181225(A3) |
申请公布日期 |
2017.01.12 |
申请号 |
WO2016IB00888 |
申请日期 |
2016.05.12 |
申请人 |
BIOVEN 3 LIMITED |
发明人 |
D'HONDT, Erik;MOLINA VILA, Miguel, Angel |
分类号 |
A61K39/00;A61K31/517;A61K31/5377;A61K31/7084;A61K39/395;A61K45/06 |
主分类号 |
A61K39/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|